Hims & Hers Health to Sell Generic GLP-1 Drugs in Canada

Dow Jones

May 21

By Elias Schisgall

Hims & Hers Health will begin selling generic GLP-1 drugs in Canada for 149 Canadian dollars ($108.41) a month.

The telehealth company will sell a generic version of Novo Nordisk's Ozempic manufactured by Apotex, a Canadian pharmaceutical firm. Apotex's drug was the second generic semaglutide treatment approved by Canadian authorities in recent weeks.

The company said its move into the Canadian obesity and diabetes market would create a more dynamic market for the drugs and meet the needs of two-thirds of Canadian adults who are overweight or obese.

"Today marks a turning point: more choice, lower costs, and a genuine commitment to care built around the whole patient," Chief Medical Officer Sandy Van said.

"Every Canadian deserves access to the treatment that's right for them, regardless of what they can afford."

Hims & Hers has previously sold its own compounded versions of semaglutide to mixed success. The company had mass-produced the drugs amid shortages of the leading branded GLP-1s, Novo's Wegovy and Eli Lilly's Mounjaro.

But legal actions from both firms prompted Hims & Hers to move away from selling its own compounded GLP-1s and toward branded drugs that have received approval in the U.S., such as Wegovy.

The company reported a loss in the first quarter, driven by a $33 million restructuring charge from write-downs related to its compounded GLP-1 supply chain.

Write to Elias Schisgall at elias.schisgall@wsj.com

(END) Dow Jones Newswires

May 21, 2026 09:35 ET (13:35 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/2637331647"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2637331647\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2637331647?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-21 21:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2637331647","market":"us","top_or_hot":-1,"title":"Hims & Hers Health to Sell Generic GLP-1 Drugs in Canada","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Hims &amp; Hers Health will begin selling generic GLP-1 drugs in Canada for 149 Canadian dollars ($108.41) a month. \n</p>\n<p>\n  The telehealth company will sell a generic version of <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>'s Ozempic manufactured by Apotex, a Canadian pharmaceutical firm. Apotex's drug was the second generic semaglutide treatment approved by Canadian authorities in recent weeks. \n</p>\n<p>\n  The company said its move into the Canadian obesity and diabetes market would create a more dynamic market for the drugs and meet the needs of two-thirds of Canadian adults who are overweight or obese. \n</p>\n<p>\n  \"Today marks a turning point: more choice, lower costs, and a genuine commitment to care built around the whole patient,\" Chief Medical Officer Sandy Van said. \n</p>\n<p>\n  \"Every Canadian deserves access to the treatment that's right for them, regardless of what they can afford.\" \n</p>\n<p>\n  Hims &amp; Hers has previously sold its own compounded versions of semaglutide to mixed success. The company had mass-produced the drugs amid shortages of the leading branded GLP-1s, Novo's Wegovy and Eli Lilly's Mounjaro. \n</p>\n<p>\n  But legal actions from both firms prompted Hims &amp; Hers to move away from selling its own compounded GLP-1s and toward branded drugs that have received approval in the U.S., such as Wegovy. \n</p>\n<p>\n  The company reported a loss in the first quarter, driven by a $33 million restructuring charge from write-downs related to its compounded GLP-1 supply chain. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 21, 2026 09:35 ET (13:35 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hims & Hers Health to Sell Generic GLP-1 Drugs in Canada</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHims & Hers Health to Sell Generic GLP-1 Drugs in Canada\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-05-21 21:35</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Hims &amp; Hers Health will begin selling generic GLP-1 drugs in Canada for 149 Canadian dollars ($108.41) a month. \n</p>\n<p>\n  The telehealth company will sell a generic version of <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>'s Ozempic manufactured by Apotex, a Canadian pharmaceutical firm. Apotex's drug was the second generic semaglutide treatment approved by Canadian authorities in recent weeks. \n</p>\n<p>\n  The company said its move into the Canadian obesity and diabetes market would create a more dynamic market for the drugs and meet the needs of two-thirds of Canadian adults who are overweight or obese. \n</p>\n<p>\n  \"Today marks a turning point: more choice, lower costs, and a genuine commitment to care built around the whole patient,\" Chief Medical Officer Sandy Van said. \n</p>\n<p>\n  \"Every Canadian deserves access to the treatment that's right for them, regardless of what they can afford.\" \n</p>\n<p>\n  Hims &amp; Hers has previously sold its own compounded versions of semaglutide to mixed success. The company had mass-produced the drugs amid shortages of the leading branded GLP-1s, Novo's Wegovy and Eli Lilly's Mounjaro. \n</p>\n<p>\n  But legal actions from both firms prompted Hims &amp; Hers to move away from selling its own compounded GLP-1s and toward branded drugs that have received approval in the U.S., such as Wegovy. \n</p>\n<p>\n  The company reported a loss in the first quarter, driven by a $33 million restructuring charge from write-downs related to its compounded GLP-1 supply chain. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 21, 2026 09:35 ET (13:35 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4144","symbol_name":"石油与天然气的储存和运输","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2637331647","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2637331647","pubTimestamp":1779370500,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Hims & Hers Health will begin selling generic GLP-1 drugs in Canada for 149 Canadian dollars  a month.The telehealth company will sell a generic version of Novo Nordisk's Ozempic manufactured by Apotex, a Canadian pharmaceutical firm. Apotex's drug was the second generic semaglutide treatment approved by Canadian authorities in recent weeks.The company said its move into the Canadian obesity and diabetes market would create a more dynamic market for the drugs and meet the needs of two-thirds of Canadian adults who are overweight or obese.\"Today marks a turning point: more choice, lower costs, and a genuine commitment to care built around the whole patient,\" Chief Medical Officer Sandy Van said.\"Every Canadian deserves access to the treatment that's right for them, regardless of what they can afford.\". Hims & Hers has previously sold its own compounded versions of semaglutide to mixed success. The company had mass-produced the drugs amid shortages of the leading branded GLP-1s, Novo's W","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4144":"石油与天然气的储存和运输","HIMS":"Hims & Hers Health Inc.","HMYY":"GraniteShares YieldBoost HIMS ETF","BK4196":"保健护理服务","BK4590":"PTP","HIMY":"Defiance Leveraged Long + Income HIMS ETF","HIYY":"YieldMax HIMS Option Income Strategy ETF","HIMZ":"DEFIANCE DAILY TARGET 2X LONG HIMS ETF"},"translate_title":"Hims&Hers Health将在加拿大销售GLP-1仿制药","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HMYY":0.6,"HIMZ":0.6,"HIMS":1.96,"HIMY":0.6,"HIYY":0.6},"content_text":"By Elias Schisgall \n\n\n \n\n\n  Hims & Hers Health will begin selling generic GLP-1 drugs in Canada for 149 Canadian dollars ($108.41) a month. \n\n\n  The telehealth company will sell a generic version of Novo Nordisk's Ozempic manufactured by Apotex, a Canadian pharmaceutical firm. Apotex's drug was the second generic semaglutide treatment approved by Canadian authorities in recent weeks. \n\n\n  The company said its move into the Canadian obesity and diabetes market would create a more dynamic market for the drugs and meet the needs of two-thirds of Canadian adults who are overweight or obese. \n\n\n  \"Today marks a turning point: more choice, lower costs, and a genuine commitment to care built around the whole patient,\" Chief Medical Officer Sandy Van said. \n\n\n  \"Every Canadian deserves access to the treatment that's right for them, regardless of what they can afford.\" \n\n\n  Hims & Hers has previously sold its own compounded versions of semaglutide to mixed success. The company had mass-produced the drugs amid shortages of the leading branded GLP-1s, Novo's Wegovy and Eli Lilly's Mounjaro. \n\n\n  But legal actions from both firms prompted Hims & Hers to move away from selling its own compounded GLP-1s and toward branded drugs that have received approval in the U.S., such as Wegovy. \n\n\n  The company reported a loss in the first quarter, driven by a $33 million restructuring charge from write-downs related to its compounded GLP-1 supply chain. \n\n\n \n\n\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 21, 2026 09:35 ET (13:35 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}